Any current/future new fundraising through debt or equity?

As per the call transcript, Atul Modi mentioned that at present, there is no capex plan because the company has already made a huge investment in the new project and R&D. The company stated there is no immediate requirement for further capital expenditure. Any future capex or fundraising needs will be evaluated and addressed as and when required. No explicit mention of any current or upcoming fundraising through debt or equity was made during the call. The focus remains on utilizing existing capacity and maintaining profitability without new debt or equity raising in the near term.

Any current/future capex/capital investment/strategic investment?

Currently, there is no immediate capex plan as the company has already made significant investments in new projects and R&D. The existing capacity is sufficient, with capability to increase production by adding shifts without new capital expenditures for several years. Any future capital expenditure will be considered as needed, but no plans are in place at present. The company is focusing on strategic investments in sales and marketing, digital marketing, e-commerce channels, new product portfolios, and increasing visibility through dental trade shows and associations. Expansion plans include

Future growth expectations in sales/revenue/volumes?

Prevest DenPro expects to double sales/revenue in the next 2-3 years due to established products and brand (Page 17). The company aims to grow market share from 2% to around 12% in the medium term (Page 17). Revenue growth guidance for next financial year is conservatively around 30%, with potential to exceed this (Page 7). Growth will be supported by a stronger sales and marketing team focused on the domestic market (Page 17). Expansion plans include increasing penetration in Indian markets by a few percentage points annually (Page 16). Existing capacity can support doubling sales without imm

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims to double its sales in the next two to three years, leveraging established product quality and a strong market presence (Page 17). Revenue growth target for the next financial year is conservatively estimated at 30%, with potential to perform better (Page 7). EBITDA margins have been strong at around 39% in recent years, with expectations to maintain or improve these margins alongside growth (Page 7, Page 9). Net profit increased by 36% in the last financial year, showing improved efficiency and effective cost management (Page 5). Earnings per share (EPS) grew signific

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders for Prevest DenPro Limited. However, it is mentioned that the company receives instant orders from foreign buyers, necessitating an increase in inventory to meet these demands (Page 12). The company is also in talks with several MNCs for large manufacturing deals and plans to enter markets like Brazil, Russia, and the US (Page 14). No specific figures or quantitative data on order books or pending orders were disclosed during the call. Overall, the company anticipates faster growth in sales

IN US

Sale is live|00:00:00left today

Prevest Denpro LtdQ1 FY23Healthcare Equipment & Supplies

Prevest Denpro Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹381P/E: 23.6Market Cap: ₹485 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Prevest DenPro expects to double sales/revenue in the next 2-3 years due to established products and brand (Page 17).
→The company aims to grow market share from 2% to around 12% in the medium term (Page 17).
→Revenue growth guidance for next financial year is conservatively around 30%, with potential to exceed this (Page 7).
→Growth will be supported by a stronger sales and marketing team focused on the domestic market (Page 17).
→Expansion plans include increasing penetration in Indian markets by a few percentage points annually (Page 16).
→Existing capacity can support doubling sales without immediate capex by adding shifts (Page 11).
→New product launches (oral hygiene, biomaterials) with better-than-existing margins are expected to contribute to growth once regulatory approvals are obtained (Page 13).
→Emphasis on digital marketing, e-commerce, and participation in dental trade shows to boost sales (Page 6).

Margin guidance

Category 3

→The company aims to double its sales in the next two to three years, leveraging established product quality and a strong market presence (Page 17).
→Revenue growth target for the next financial year is conservatively estimated at 30%, with potential to perform better (Page 7).
→EBITDA margins have been strong at around 39% in recent years, with expectations to maintain or improve these margins alongside growth (Page 7, Page 9).
→Net profit increased by 36% in the last financial year, showing improved efficiency and effective cost management (Page 5).
→Earnings per share (EPS) grew significantly, with FY22-23 EPS at INR 13.09, reflecting strong value creation for shareholders (Page 5).
→Margin maintenance is a key focus while scaling; cost pressures related to increased sales and marketing are expected but margins will be preserved (Page 17).

3 more insights locked — sign up free to unlock

Fundraise plans

→As per the call transcript, Atul Modi mentioned that at present, there is no capex plan because the company has already made a huge investment in the new project and R&D.
→The company stated there is no immediate requirement for further capital expenditure.
→Any future capex or fundraising needs will be evaluated and addressed as and when required.
→No explicit mention of any current or upcoming fundraising through debt or equity was made during the call.
→The focus remains on utilizing existing capacity and maintaining profitability without new debt or equity raising in the near term.

Order book

→The transcript does not provide explicit details on the current or expected order book or pending orders for Prevest DenPro Limited.
→However, it is mentioned that the company receives instant orders from foreign buyers, necessitating an increase in inventory to meet these demands (Page 12).
→The company is also in talks with several MNCs for large manufacturing deals and plans to enter markets like Brazil, Russia, and the US (Page 14).
→No specific figures or quantitative data on order books or pending orders were disclosed during the call.
→Overall, the company anticipates faster growth in sales and market share, with new product lines ready for commercialization pending regulatory approvals, suggesting an optimistic order pipeline.

Capex plans

→Currently, there is no immediate capex plan as the company has already made significant investments in new projects and R&D.
→The existing capacity is sufficient, with capability to increase production by adding shifts without new capital expenditures for several years.
→Any future capital expenditure will be considered as needed, but no plans are in place at present.
→The company is focusing on strategic investments in sales and marketing, digital marketing, e-commerce channels, new product portfolios, and increasing visibility through dental trade shows and associations.
→Expansion plans include building a new facility to increase capacity, but this does not currently imply immediate capex beyond existing allocations.

How does Prevest Denpro Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

1Prevest Denpro Ltd

Rev 2Mar 3

See full Healthcare Equipment & Supplies sector rankings

Want more stocks like Prevest Denpro Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio